Clinical Trials Show Promise for Parkinson's Cell Therapy

Stem cell therapy for Parkinson's disease has reached a critical turning point, with multiple clinical trials demonstrating that transplanting dopamine-producing neurons into patients' brains can be done safely and may alleviate the motor symptoms that define this progressive neurological disorder. Two major phase 1 trials published in Nature during 2025 tested different stem cell sources, one using induced pluripotent stem cells derived from adult blood in Japan, and another using human embryonic stem cells in a collaboration between researchers at UC Irvine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and the University of Toronto. Both studies involved surgical transplantation of early stage dopamine-producing cells directly into the putamen, a brain region critical for movement control. The trials enrolled a total of 19 participants with Parkinson's, all of whom received varying dose of the cellular therapy. Remarkably, after 18 to 24 months of follow-up, neither study reported serious adverse events related to the cell transplants, no tumor formation, and no dyskinesias induced by the transplanted cells; complications that had plagued earlier attempts at cell therapy decades ago. 

Beyond establishing safety, both trials showed preliminary evidence of therapeutic benefit. In the Japanese trial using induced pluripotent stem cells, brain imaging revealed an average 44.7% increase in dopamine activity in the putamen, with participants in the higher-dose group experiencing the most substantial gains. Most participants demonstrated measurable improvements in movement symptoms whether they were on or off their regular Parkinson's medications. The North American trial using human embryonic stem cells reported similar findings: imaging studies confirm that transplanted cell survived and integrated into brain tissue even after immunosuppression medications were discontinued at 12 months, and participants receiving higher doses should an average 23-point improvement in their Parkinson's rating scale scores when off medication. While these improvements varied among individuals and require validation in larger studies, the consistency of results across different stem cell sources suggests the underlying biological principle is sound.

The genetic and regenerative medicine implications of this work extend well beyond Parkinson's treatment. These trials represent some of the most advanced applications of pluripotent stem cell technology in human neurodegenerative disease, demonstrating that scientists can guide stem cells to differentiate into specific neuron types and successfully integrate them into complex neural circuits. The University of Wisconsin's preliminary work using autologous induced pluripotent stem cells, cells derived from patient's own tissue, offers an additional advantage by potentially eliminating the need for long-term immunosuppression, though this approach requires personalized cell manufacturing for each patient. At phase three trials prepared to launch later in 2025 including UC Irvine's Alva Clinic the field stands at the threshold of potentially transforming Parkinson's from a disease management medications that lose effectiveness over time into one where neural networks can be rebuilt through a single surgical procedure the shift from symptomatic management to regenerative repair represents a fundamental reimagining of how neurodegenerative diseases might be treated in the coming decades.

Sources:

“Cell Therapy for Parkinson’s Shows Promise.” School of Medicine and Public Health, 16 Oct. 2025, www.med.wisc.edu/news/cell-therapy-for-parkinsons/.

“Stem-Cell Therapy Is a ‘big Leap’ for Parkinson’s Treatment.” UCI Health, 16 Apr. 2025, www.ucihealth.org/about-us/news/2025/04/parkinsons-study-nature.

“Two New Trials Explore Stem-Cell Therapy for Parkinson’s.” Parkinson’s Foundation, 8 May 2025, www.parkinson.org/blog/science-news/cell-replacement.

She Was Born Without an Immune System. Gene Therapy Saved Her Life.

The article explains how gene therapy saved the life of a young girl, Cora Oakley, who was born with severe combined immunodeficiency (SCID). SCID is a rare genetic disorder that leaves babies without a functioning immune system. SCID is often referred to as "bubble boy disease," and it used to be considered a death sentence. Patients with this condition traditionally receive a bone-marrow transplant, but that carries serious risks, including graft vs host disease, long hospitalizations, infertility, and long-term organ damage.

The young child had ADA-SCID, which is one of the few variants of SCID that is targeted by a new form of a gene therapy trial from 2017. Instead of trying to replace her immune system, her doctors decided to collect her stem cells, insert a healthy ADA gene using a modified HIV virus, and return the corrected cells to her body. 

A study done recently that followed 62 babies found that every child was alive after eight years, and 95% had a fully restored immune system. The treatment for this condition is now much less dangerous for patients, and families are overall happier with this treatment. Although this treatment is costly for families.

This type of gene therapy saved Cora's life, as well as many other patients. She and many others can now live a healthy, normal life due to gene therapy. This article was refreshing to read to see good news occurring because of gene therapy.

References:

Bajaj, S. (2025, December 1). Gene therapy offer a cure for babies with the deadly ‘bubble boy disease’ - the new york times. https://www.nytimes.com/2025/11/27/well/bubble-boy-disease-gene-therapy.html

Wadbudhe, A. M., Meshram, R. J., & Tidke, S. C. (2023, October 26). Severe combined immunodeficiency (SCID) and its new treatment modalities. Cureus. https://pmc.ncbi.nlm.nih.gov/articles/PMC10676291/

World's First Recipient Of Personalized Gene Editing Treatment Lives

                   CPS1 deficiency, a rare genetic disorder affects one in 1.3 million babies. Only half of babies diagnoses with this disorder make it past the first week. If they do survive that long they would have severe mental and developmental delays and eventually need liver transplants. Their bodies are unable to rid themselves of ammonia, a byproduct of protein metabolism which build up in the blood and crosses into the brain. However, KJ’s parents decided to try something new. In New York Time’s article Baby Is Healed With World’s First Personalized Gene-Editing Treatment, Baby KJ was reported to be the first recipient in the world to receive a custom gene editing treatment. KJ’s treatment was customized so CRISPR, a gene editing tool that finds and cuts specific sequences, found just his single point mutation causing this fatal genetic disorder. Every treatment he receives requires a lower and lower dose. Now over 9 ½ months old and thriving, KJ’s trial opens the door to vast possibilities in gene editing field. 

        What does this mean for others? Parents facing a CPS1 deficiency diagnosis for their child now doesn’t necessarily mean an early end and severely impacted quality of life. Cleveland Clinic estimates there could be as many as 7,000 genetic diseases and disorders that can now be reexamined to find a cure. With living proof this technology works it could potentially be applied to infinites cases and varying severities. 

A New Chapter in Gene Therapy

        Recent advances in gene editing are turning what once seemed like science fiction into real treatments. One striking example is a personalized therapy developed for a baby born with a rare metabolic disorder. Researchers at Children's Hospital of Philadelphia and Penn Medicine used a base-editing version of the CRISPR-Cas9 system to correct a mutation in the CPS1 gene of a child who suffered from carbamoyl phosphate synthetase 1 deficiency. Within months of receiving the therapy, the child was able to tolerate increased protein in his diet and required fewer nitrogen-scavenging medications.

        This breakthrough shows the feasibility of tailored gene-editing for ultra rare diseases, where traditional drug development isn't practical. However, as discussed in Innovative Genomics Institute's review, the case raises ethical questions about cost, accessibility, and equity in access to gene therapy.  

New gene-editing tech holds promise for treating complex genetic diseases

There are researchers that are currently working at the University of Texas and are trying to find more effective methods to treat genetic disorders. They are using bacterial elements called retrons, with a new system in place that can repair multiple mutations at once instead of the traditional one. This is incredibly helpful, especially for diseases such as cystic fibrosis which have many of the same mutations within one gene. The retron based method is known to work effectively, while adjusting cells by 30%. By adjusting the large defective sections of DNA with healthier ones, this could lead to more inclusive and cheaper gene therapies. A graduate student from UT said “My hope, and what drives me, is to develop a gene-editing technology that’s much more inclusive of people who might have more unique disease-causing mutations, and that using retrons will be able to expand that impact onto a much broader patient population” (New gene-editing tech holds promise for treating complex genetic diseases, 2025).

The new method is giving researchers hope since it can replace a large quantity of the defective DNA in a healthy sequence. This can also fix any type of combination of mutations in the DNA strand without having to “be specific to any one person’s genetics”. This discovery is a huge step towards better genetic treatment options. This offers help for individuals with really rare mutations who are usually left with little to no effective options. 

 

Gene therapy for cystic fibrosis. Cystic Fibrosis Foundation. (n.d.). https://www.cff.org/research-clinical-trials/gene-therapy-cystic-fibrosis 

UTAustin. (n.d.). New gene-editing Tech holds promise for treating complex genetic diseases. EurekAlert! https://www.eurekalert.org/news-releases/1102990

Cutting-Edge Cancer Treatment is not Known by Most Americans

     On Monday, April 21, 2025 Dennis Thompson a HealthDay Reporter announced a story of a man named Chris Vogelsang who had a long terrible fight with cancer. About fourteen years ago, the 70 year old man was first diagnosed with an aggressive form of lymphoma. His cancer had returned twice while fighting against several rounds of different treatments that consisted of a full blown stem cell replacement. He stated that his energy levels were very low, while he was losing weight and had constant night sweats. He had then discovered that he was 90% involved with lymphoma cells within his bone marrow. His all time question was "What do I have to do to get through it so I can get on with my life?" The answers turned out to be a cutting edge treatment that very few Americans had known about. It was a CAR T-cell therapy that uses advanced gene therapy to teach a person's immune system how to target and destroy their cancer. However only about two-thirds of Americans (65%) are unaware of this personalized cancer treatment which is unfortunate. During CAR T-cell therapy, doctors are able to extract hunter/killer immune cells called T-cells from an individuals blood. Then lab technicians analyze a person's cancer and find targets on their cancer cells that could be used to find and kill them. The techs are able to genetically engineer the T-cells to seek out the specific targets and attacks the cancer, when the immune cells are then put back in the individuals body in their IV. The results of CAR T-cell therapy have been highly promising with more than half of lymphoma patients achieving remission. For the time being CAR T-cell therapy is only approved by the U.S. Food and Drug Administration for only certain types of blood cancers, however doctors are trying to work on ways that will extend this personalized therapy so that it can be used to treat solid tumors as well. This is such a huge improvement to medicine, it is unfortunate that this type of treatment is not widely known or used to help treat patients. 

Links:

https://www.usnews.com/news/health-news/articles/2025-04-21/cutting-edge-cancer-treatment-isnt-known-by-most-americans

https://pubmed.ncbi.nlm.nih.gov/38877876/

   

Mutated DNA Fixed in Patients: A Huge Step for Gene Therapy

A recent article by Gina Kolata, published on March 10, 2025 in The New York Times, discusses an exciting breakthrough in gene therapy. Scientists have succesfully fixed a genetic mutation with a single infusion carrying a treatment that precisely targets the mutated gene. This is for the first time that a mutated gene has been returned to normal. This study led by Beam Therapeauticals, focused on alpha-1 antitrypsin deficiency (AATD), which is a genetic disorder that causes serious lung and liver damage and instead of using traditional gene therapy which involve adding or silencing genes, scientists used a special version of CRISPR to edit a single DNA letter, like "correcting a typo" in the genetic code. The patients who received highest doses started making normal levels of the missing protein, which could mean stopping the disease before it gets worse.

        This coud be a turning point in gene therapy, proving fixing faulty DNA inside the body is possible and what's more interesting is that, according to Beam's CEO, John Evans there were no serious side effects. While researchers still have to study long term effects, if further trials confirms it's safety, this could save countless lives and maybe it could pave the way for treating other genetic disorders like sickle cell anemia. The idea of editing DNA, like fixing a typo is something that holds the potential to save many people suffering from genetic disorders.

Nanoparticles Used to Perform Gene Editing in the Lungs.

 

Researchers at MIT have found a new way to administer nanoparticles which contain mRNA with CRISPR/Cas 9 components, to the lungs. The main goal of the project was to find a more efficient way to administer drugs. In the past injections and oral forms have been used however researchers find that these pathways might not be the most efficient. As a result, their main target was to create medication that could be inhaled almost like a nebulizer. This concept was first tested on mice with the nanoparticles containing a gene for a fluorescent protein. Scientists then measured what percent of the mice showed fluorescence in the lungs. After three doses, scientists found that almost 60% of the lung epithelial cells had fluorescence. In addition, for lung diseases, the two cells which are most affected are ciliated cells and club cells. They showed a fluorescence of 15%. This method of drug administration is also very effective as the lungs are cleared within 3 days avoiding any inflammation. Scientists are still working on making these particles more stable so they can be aerosolized. The main goal of this project is to correct the genetic mutations caused by cystic fibrosis and other forms of lung disease. 

This study is very insightful because drugs for lung disease are rarely ever inhaled and used in the form of a nebulizer. In many cases, the current drugs can be very inefficient as they often have side effects and don’t target the lungs specifically. However this study gives insight on how future medications might work when it comes to treating lung disease. This project is also very important because it showed that drugs like these can be produced in mass quantities. This is a very important aspect of drug development as if a drug cannot be produced in mass quantities then it can be very hard for the general population to take advantage of it. Overall this study shows a bright future when it comes to the treatment of lung diseases. 

Links: https://news.mit.edu/2023/new-nanoparticles-can-perform-gene-editing-lungs-0330

https://www.nature.com/articles/s41467-020-17029-3